The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide
Abstract
Three random basic copolymers of amino acids were tested for their effect on experimental allergic encephalomyelitis (EAE). One of these copolymers denoted as Cop 1, composed of alanine, glutamic acid, lysine and tyrosine, with a molecular weight of 23 000, showed a marked suppressive effect on the disease. The intravenous administration of Cop 1 in physiological saline, as late as 5 days following the challenge with the disease‐inducing dose of the basic encephalitogenic protein, reduced the clinical incidence of EAE from 64% in the control group to 22%; the histological lesions were also decreased both in prevalence and in severity. The suppressive effect on the disease attained by the synthetic copolymer is of the same order of magnitude as that previously reported for the basic encephalitogen. The effect of the copolymers appears to be specific, since neither an acidic amino acid copolymer, nor unrelated basic proteins, had any protective action. On the other hand, a second batch of Cop 1 showed activity identical to that of the first batch. The potential applicability of this non‐encephalitogenic and non‐immunosuppressive material is discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Automatic Recording Apparatus for Use in Chromatography of Amino Acids
Spackman, D. H., Stein, W. H., & Moore, S. (1958) · Analytical Chemistry · doi:10.1021/ac60139a006 · Cited by 9,585
Equilibrium Ultracentrifugation of Dilute Solutions*
Yphantis, D. A. (1964) · Biochemistry · doi:10.1021/bi00891a003 · Cited by 3,384
Handbook of Experimental Immunology.
(1968) · Annals of Internal Medicine · doi:10.7326/0003-4819-68-6-1376_1 · Cited by 2,408
ENCEPHALOMYELITIS ACCOMPANIED BY MYELIN DESTRUCTION EXPERIMENTALLY PRODUCED IN MONKEYS
Rivers, T. M., & Schwentker, F. F. (1935) · Journal of Experimental Medicine · doi:10.1084/jem.61.5.689 · Cited by 435
Experimental allergic encephalomyelitis
Eylar, E. H., Salk, J., Beveridge, G. C., & Brown, L. V. (1969) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(69)90336-1 · Cited by 402
Cleavage of N-Carbobenzoxy Groups by dry Hydrogen Bromide and Hydrogen Chloride
Ben‐Ishai, D., & Berger, A. (1952) · The Journal of Organic Chemistry · doi:10.1021/jo50012a002 · Cited by 379
Leuchs, H. (1906) · Berichte der deutschen chemischen Gesellschaft · doi:10.1002/cber.190603901133 · Cited by 332
Experimental Allergic Encephalomyelitis and Autoimmune Disease
Paterson, P. Y. (1966) · Advances in Immunology · doi:10.1016/s0065-2776(08)60273-4 · Cited by 278
Synthesis and Chemical Properties of Poly-α-Amino Acids
Katchalski, E., & Sela, M. (1958) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60600-2 · Cited by 273
Self-citationGoldberger, R. F., & Anfinsen, C. B. (1962) · Biochemistry · doi:10.1021/bi00909a005 · Cited by 160
Cited by
Trends in peptide drug discovery
Muttenthaler, M., King, G. F., Adams, D. J., & Alewood, P. F. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00135-8 · Cited by 1,964
Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)
Constantinescu, C. S., Farooqi, N., O'Brien, K., & Gran, B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01302.x · Cited by 1,523
Gold, R. (2006) · Brain · doi:10.1093/brain/awl075 · Cited by 1,017
“Currently, the only effective antigen-specific therapy is glatiramer acetate (Teitelbaum et al., 1971), developed as a bystander product in EAE studies and soon transferred into multiple sclerosis therapy (Abramsky et al., 1977).”
BackgroundT cells in multiple sclerosis and experimental autoimmune encephalomyelitis
Fletcher, J. M., Lalor, S. J., Sweeney, C. M., Tubridy, N., & Mills, K. H. G. (2010) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2010.04143.x · Cited by 945
Steinman, L., & Zamvil, S. S. (2006) · Annals of Neurology · doi:10.1002/ana.20913 · Cited by 479
The experimental autoimmune encephalomyelitis (EAE) model of MS
(2014) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-52001-2.00008-x · Cited by 464
A Pilot Trial of Cop 1 in Exacerbating–Remitting Multiple Sclerosis
Bornstein, M. B., Miller, A., Slagle, S., Weitzman, M., Crystal, H., Drexler, E., Keilson, M., Merriam, A., Wassertheil-Smoller, S., Spada, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198708133170703 · Cited by 462
Self-citationThe origin and application of experimental autoimmune encephalomyelitis
Baxter, A. G. (2007) · Nature Reviews Immunology · doi:10.1038/nri2190 · Cited by 458
Duda, P. W., Schmied, M. C., Cook, S. L., Krieger, J. I., & Hafler, D. A. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8970 · Cited by 416
Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease
Monsonego, A., Zota, V., Karni, A., Krieger, J. I., Bar-Or, A., Bitan, G., Budson, A. E., Sperling, R., Selkoe, D. J., & Weiner, H. L. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318104 · Cited by 367
“To determine whether the increased Aβ responses seen in our elderly and AD groups were also observed for other T cell responses, we examined T cell responses to αCD3/CD28 antibodies and to a universal antigen that stimulates T cells through the T cell receptor (TCR), GA (45).”
BackgroundKipnis, J., Yoles, E., Porat, Z., Cohen, A., Mor, F., Sela, M., Cohen, I. R., & Schwartz, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.13.7446 · Cited by 308
Self-citationNeuhaus, O., Farina, C., Yassouridis, A., Wiendl, H., Then Bergh, F., Dose, T., Wekerle, H., & Hohlfeld, R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.13.7452 · Cited by 299
Schori, H., Kipnis, J., Yoles, E., WoldeMussie, E., Ruiz, G., Wheeler, L. A., & Schwartz, M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.041609498 · Cited by 286
Aharoni, R., Teitelbaum, D., Sela, M., & Arnon, R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10821 · Cited by 274
Self-citationVirtues and pitfalls of EAE for the development of therapies for multiple sclerosis
Steinman, L., & Zamvil, S. S. (2005) · Trends in Immunology · doi:10.1016/j.it.2005.08.014 · Cited by 265
Experimental Autoimmune Encephalomyelitis (EAE) as Animal Models of Multiple Sclerosis (MS)
Glatigny, S., & Bettelli, E. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a028977 · Cited by 247
Glatiramer acetate: Mechanisms of action in multiple sclerosis
Schrempf, W., & Ziemssen, T. (2007) · Autoimmunity Reviews · doi:10.1016/j.autrev.2007.02.003 · Cited by 168
Glatiramer acetate: mechanisms of action in multiple sclerosis.
Ziemssen, T., & Schrempf, W. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(07)79024-4 · Cited by 135
Update on Disease-Modifying Treatments for Multiple Sclerosis
Carrithers, M. D. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.08.006 · Cited by 55
Huntemann, N., Vogelsang, A., Groeneweg, L., Willison, A., Herrmann, A. M., Meuth, S. G., & Eichler, S. (2022) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2021.109443 · Cited by 23
“Natalizumab, one of the most effective agents currently available (Wiendl and Meuth, 2015), was pioneered in EAE and successfully translated into clinical practice.”
Background
Metadata
- Authors
- Teitelbaum, D., Meshorer, A., Hirshfeld, T., Arnon, R., & Sela, M.
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 1971-01
- Volume
- 1
- Issue
- 4
- Pages
- 242-248
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W2104377381
- Cited by
- 433
- References
- 16
- FWCI
- 5.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.